Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Central Nervous System Neoplasms 6Astrocytoma 5Oligodendroglioma 4Optic Nerve Glioma 3Medulloblastoma 3Gliosarcoma 3Glioblastoma 3Familial ependymoma 3Choroid Plexus Neoplasms 3Lymphoma, T-Cell, Cutaneous 2Brain Neoplasms 2Wilms Tumor 1Unspecified Adult Solid Tumor, Protocol Specific 1Testicular Neoplasms 1Teratoma 1Sezary Syndrome 1Sarcoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Mycosis Fungoides 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Glioma 1Ependymoma 1

Interventions

aldesleukin 65Cyclophosphamide 45fludarabine phosphate 30fludarabine 27Interleukin-2 24incomplete Freund's adjuvant 22Ipilimumab 17Specimen Handling 14MART-1 Antigen 14CTLA-4 Antigen 14sargramostim 13Magnetic Resonance Spectroscopy 13Biopsy 13montanide ISA 51 11Nivolumab 11Filgrastim 11Sorafenib 10Interferon-alpha 9trametinib 8pembrolizumab 8dabrafenib 8Sirolimus 7Bevacizumab 7temsirolimus 6Temozolomide 6Taxes 5Paclitaxel 5Introns 5Gene Expression Profiling 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Melanoma × O(6)-benzylguanine × Clear all
NCT00005961 2013-02-11

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡